02/12
Headlines

NASDAQ:HALO

Oversold Stocks In News: Halozyme Therapeutics (NASDAQ:HALO), Lumos Networks (NASDAQ:LMOS), Advaxis (NASDAQ:ADXS), Sterling Construction Company (NASDAQ:STRL)

Jayne Crisman02 mins

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported that the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial. Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock performance was -0.93% in last session and finished the day at $7.42. Traded…

Read More

Biotech Active runners: Arena Pharmaceuticals (NASDAQ:ARNA), Halozyme Therapeutics (NASDAQ:HALO), Gildan Activewear (NYSE:GIL), Ariad Pharmaceuticals (NASDAQ:ARIA)

Jason Knox02 mins

Sales of the Arena Pharmaceuticals Inc (NASDAQ:ARNA) anti-obesity drug Belviq have closed out the quarter on a positive note. Sales improved throughout the quarter and are pacing well ahead of the previous quarter. Though this week’s sales only take us to March 28th, there is enough here for us to assess the sales activity, project…

Read More

Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

Mark Doerr03 mins

The only therapy currently approved by the Food and Drug Administration to treat myelofibrosis, a disorder where abnormal blood cells build up inside a patient’s bone marrow, is Incyte (NASDAQ:INCY) and Novartis’ Jakafi (known as Jakavi outside the U.S.), which is a JAK2 inhibitor. JAK2 is an enzyme that plays a key role in signal…

Read More

Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Mark Doerr02 mins

Novavax, Inc. (NASDAQ:NVAX) is a vaccine company that is likely to have multiple milestones this year. It has U.S. government funding for seasonal and pandemic flu, and is developing its own products for respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) stock performance was -5.02% in last session and finished the day at $6.05. Traded volume…

Read More

Biotech Gainers: Insys Therapeutics Inc (NASDAQ:INSY), Oxygen Biotherapeutics (NASDAQ:OXBT), Halozyme Therapeutics (NASDAQ:HALO), Cytori Therapeutics (NASDAQ:CYTX)

Mark DeFrance02 mins

Insys Therapeutics (NASDAQ:INSY) hit a new 52-week high during trading on Tuesday following a better than expected earnings announcement, AnalystRatings.NET reports. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was 21.73% in last session and finished the day at $83.37. Traded volume was 1,203,992 million shares in the last session and the average volume of the stock…

Read More